CYP2D6 and psychotic disorder: Currently, only psychosis drugs with PGx associations for the CYP2D6 gene have been assigned the highest level of evidence (LoE) and have clinical dosing guidance (see Supplemental Appendix A) (DPWG, 2022; Murphy et al., 2022).